COMPASS Pathways plc (NASDAQ:CMPS) Receives $30.67 Consensus Price Target from Analysts

Shares of COMPASS Pathways plc (NASDAQ:CMPS - Get Free Report) have been assigned an average rating of "Buy" from the seven analysts that are currently covering the company, Marketbeat.com reports. Seven research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $30.67.

CMPS has been the subject of a number of recent research reports. Royal Bank of Canada dropped their target price on COMPASS Pathways from $23.00 to $18.00 and set an "outperform" rating for the company in a report on Friday, November 1st. HC Wainwright dropped their target price on COMPASS Pathways from $120.00 to $60.00 and set a "buy" rating for the company in a report on Friday, November 1st. Canaccord Genuity Group dropped their target price on COMPASS Pathways from $50.00 to $48.00 and set a "buy" rating for the company in a report on Friday, August 2nd. Maxim Group decreased their price target on COMPASS Pathways from $22.00 to $12.00 and set a "buy" rating for the company in a research note on Friday, November 1st. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of COMPASS Pathways in a research note on Monday, September 9th.

Insider Buying and Selling at COMPASS Pathways

In other COMPASS Pathways news, major shareholder Life Sciences N.V. Atai sold 2,660,000 shares of COMPASS Pathways stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $6.05, for a total transaction of $16,093,000.00. Following the completion of the sale, the insider now directly owns 6,905,774 shares of the company's stock, valued at $41,779,932.70. The trade was a 27.81 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.25% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Logos Global Management LP increased its holdings in shares of COMPASS Pathways by 349.3% in the 2nd quarter. Logos Global Management LP now owns 1,159,030 shares of the company's stock valued at $7,001,000 after acquiring an additional 901,050 shares during the period. Sio Capital Management LLC increased its holdings in shares of COMPASS Pathways by 211.7% in the 3rd quarter. Sio Capital Management LLC now owns 914,639 shares of the company's stock valued at $5,762,000 after acquiring an additional 621,222 shares during the period. Rosalind Advisors Inc. increased its holdings in shares of COMPASS Pathways by 6.5% in the 3rd quarter. Rosalind Advisors Inc. now owns 781,423 shares of the company's stock valued at $4,923,000 after acquiring an additional 47,423 shares during the period. Polar Asset Management Partners Inc. increased its holdings in shares of COMPASS Pathways by 83.3% in the 3rd quarter. Polar Asset Management Partners Inc. now owns 567,600 shares of the company's stock valued at $3,576,000 after acquiring an additional 258,000 shares during the period. Finally, Acuta Capital Partners LLC purchased a new position in shares of COMPASS Pathways in the 3rd quarter valued at $2,435,000. 46.19% of the stock is currently owned by hedge funds and other institutional investors.

COMPASS Pathways Stock Performance

Shares of NASDAQ:CMPS traded up $0.16 during midday trading on Monday, reaching $4.57. 821,098 shares of the company's stock traded hands, compared to its average volume of 633,850. The company has a market cap of $312.68 million, a price-to-earnings ratio of -2.08 and a beta of 2.29. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.91 and a current ratio of 8.91. COMPASS Pathways has a one year low of $4.05 and a one year high of $12.75. The stock has a 50 day moving average of $5.85 and a 200 day moving average of $6.65.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last released its earnings results on Thursday, October 31st. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.04. During the same period in the previous year, the firm posted ($0.67) EPS. As a group, equities research analysts anticipate that COMPASS Pathways will post -2.33 EPS for the current fiscal year.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.